title: Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program.
abstract: Until recently, the collection of peripheral blood progenitor cells (PBPC) has been semi-automated by using the COBE Spectra, with the operator manually maintaining the position of the white cells being collected. The COBE Spectra Version 6.0 apheresis device offers the user an automated program for the collection of PBPC. In this study, we compared the new software Version 6.0 to that of Version 4.7. Patients (n = 46) undergoing PBPC collection were allocated to cell processing with either Version 4.7 (n = 24) or Version 6.0 (n = 22). The CD34+ cell count, mononuclear cell (MNC) count, white cell count (WCC), hemoglobin (Hb), and platelet content in the autograft product by using the two versions were compared. We divided the analysis into three subsets according to peripheral blood (PB) CD34 content: <10x10(6)/L, 10-50x10(6)/L and >50x10(6)/L. Analysis of the three subsets showed no statistical difference between results obtained when the starting PB CD34+ cell count was 10-50x10(6)/L (P=0.08) or >50x10(6)/L (P=0.4065). At lower starting PB CD34+ cell counts of <10x10(6)/L, Version 4.7 was superior (P=0.0167). However, autograft platelet contamination of the autograft was significantly higher using Version 4.7 (P=<0.0001).
authors.affiliation: Autologous Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Wilke
authors.forename: M
authors.initials: M
authors.lastname: Brettell
authors.forename: H M
authors.initials: HM
authors.lastname: Prince
authors.forename: M
authors.initials: M
authors.lastname: Wolf
authors.forename: R
authors.initials: R
authors.lastname: McKenna
authors.forename: E
authors.initials: E
authors.lastname: Serpell
authors.forename: M
authors.initials: M
authors.lastname: Molloy
authors.forename: H
authors.initials: H
authors.lastname: Stevens
authors.forename: M
authors.initials: M
authors.lastname: Quinn
authors.forename: P
authors.initials: P
authors.lastname: Gates
authors.forename: P
authors.initials: P
authors.lastname: Chapple
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001331:Automation; D003520:Cyclophosphamide / Q000494:pharmacology; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000295:instrumentation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007937:Leukapheresis / Q000295:instrumentation*; D007958:Leukocyte Count / Q000295:instrumentation*; D009369:Neoplasms / Q000097:blood; D011994:Recombinant Proteins; D012984:Software; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D000069585:Filgrastim